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Objective: To compare the prognostic accuracy of Prostate Health Index (PHI) and Prostate Cancer Antigen 3 in predicting pathologic
features in a cohort of patients who underwent radical prostatectomy (RP) for prostate cancer (PCa).
Methods and materials: We evaluated 156 patients with biopsy-proven, clinically localized PCa who underwent RP between January
2013 and December 2013 at 2 tertiary care institutions. Blood and urinary specimens were collected before initial prostate biopsy for [-2]
pro–prostate-speciﬁc antigen (PSA), its derivates, and PCA3 measurements. Univariate and multivariate logistic regression analyses were
carried out to determine the variables that were potentially predictive of tumor volume 40.5 ml, pathologic Gleason sumZ7,
pathologically conﬁrmed signiﬁcant PCa, extracapsular extension, and seminal vesicles invasions.
Results: On multivariate analyses and after bootstrapping with 1,000 resampled data, the inclusion of PHI signiﬁcantly increased the
accuracy of a baseline multivariate model, which included patient age, total PSA, free PSA, rate of positive cores, clinical stage, prostate
volume, body mass index, and biopsy Gleason score (GS), in predicting the study outcomes. Particularly, to predict tumor volume40.5, the
addition of PHI to the baseline model signiﬁcantly increased predictive accuracy by 7.9% (area under the receiver operating characteristics
curve [AUC] ¼ 89.3 vs. 97.2, P4 0.05), whereas PCA3 did not lead to a signiﬁcant increase.
Although both PHI and PCA3 signiﬁcantly improved predictive accuracy to predict extracapsular extension compared with the baseline
model, achieving independent predictor status (all P's o 0.01), only PHI led to a signiﬁcant improvement in the prediction of seminal
vesicles invasions (AUC ¼ 92.2, Po 0.05 with a gain of 3.6%).
In the subset of patients with GSr 6, PHI signiﬁcantly improved predictive accuracy by 7.6% compared with the baseline model (AUC ¼
89.7 vs. 97.3) to predict pathologically conﬁrmed signiﬁcant PCa and by 5.9% compared with the baseline model (AUC ¼ 83.1 vs. 89.0) to
predict pathologic GSZ 7. For these outcomes, PCA3 did not add incremental predictive value.
Conclusions: In a cohort of patients who underwent RP, PHI is signiﬁcantly better than PCA3 in the ability to predict the presence of
both more aggressive and extended PCa. r 2014 Elsevier Inc. All rights reserved.
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Most recent data from European Study of Screening for
Prostate Cancer reported a 21% relative reduction in the
risk of death due to prostate cancer (PCa) at 13 years of
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participation [1] and the Goteborg study, one of the European
Study of Screening for Prostate Cancer centers, showed a
44% relative reduction at 14 years of follow-up [2]; however,
currently, population screening for PCa remains controver-
sial. The most important reason for controversy is the high
percentage of overdiagnosis, calculated as ranging from 1.7%
to 67% according to the different designs of the studies
(epidemiological, clinical, and autopsy studies) and the
consequent overtreatment [3]. However, in the current
clinical practice, the increasing use of prostate-speciﬁc
antigen (PSA) for the detection of PCa, in an “opportunistic”
screening scenario, has already led to an important increase
in incidence of diagnosed low-risk PCa that may not
clinically progress during lifetime [4]. The preoperative tools
currently used in this clinical setting, such as PSA, digital
rectal examination, and biopsy results fail to accurately
predict PCa aggressiveness and distinguish between insig-
niﬁcant PCa, eligible for protocol of active surveillance (AS)
or focal therapy, and clinically signiﬁcant PCa, eligible for
radical prostatectomy (RP) or radiation therapy.
Consequently, numerous predictive and prognostic tools
have been recently introduced to assist the physicians in the
clinical decision-making process. However, these available
models are far from perfect in their predictive ability and
new biomarkers are required to correctly stratify patient risk
before treatment.
In this context, several studies have analyzed the
capability of prostate cancer antigen 3 (PCA3) [5–11] and
[-2] proPSA (p2PSA) and its derivative, %[-2] proPSA
(%p2PSA), and Prostate Health Index (PHI) [12–15] in
predicting PCa characteristics at ﬁnal pathology in different
and separate study cohorts.
Currently, no evidence is available on the prognostic and
pathologic comparison of PCA3 and PHI in a same study
cohort at the time of RP.
The aim of this study is to compare the prognostic
accuracy of PCA3 and PHI in predicting pathologic features
in a cohort of patients who underwent RP for clinically
localized PCa.2. Material and methods
2.1. Study design
The current study is a prospective, observational cohort
study, carried out between January 2013 and December
2013, of patients recruited at 2 tertiary care institutions:
University of Catanzaro and National Institute of Cancer,
Naples.
The study was designed according to the Standards for
the Reporting of Diagnostic Accuracy Studies methodology
to test the sensitivity, speciﬁcity, and accuracy of p2PSA,
its derivates, and PCA3 in predicting pathologic features at
the time of RP (http://www.stard-statement.org).2.2. Study population and clinical evaluation
We included 156 patients with biopsy-proven, clinically
localized PCa who underwent, within 3 months of diag-
nosis, laparoscopic or robot-assisted laparoscopic RP. None
of the study patients received neoadjuvant hormonal ther-
apy (antiandrogens or luteinizing hormone–releasing hor-
mone analogues or antagonists) or other hormonal
preparations (i.e., 5-α reductase inhibitors) that could alter
their PSA values. We also excluded patients with bacterial
acute prostatitis or previous prostate surgery in the 3 months
before biopsy. In addition, subjects with chronic renal
disease, marked alterations in blood protein levels (plasma
normal range: 6–8 g/100 ml), hemophilia, or those previ-
ously multiply transfused were excluded from the study
because these conditions could alter the concentration of
free PSA (fPSA) and, consequently, of p2PSA, as the
p2PSA is a molecular isoform of fPSA [13].
The local hospital ethics committee approved the study
protocol and all participants signed written informed
consents.
Blood specimens were collected before initial prostate
biopsy. Whole blood was allowed to clot before the serum
was separated by centrifugation. Serum aliquots were stored
at 801C until the samples were processed, as given by
Semjonow et al. [16]. Specimens were analyzed in a blinded
fashion for PSA, fPSA, and p2PSA by Access 2 Immuno-
assay System analyzer (Beckman Coulter, Brea, CA).
First-catch urine samples were also collected before
prostate biopsy and following an attentive digital rectal
examination (3 strokes per lobe) and stored in a Progensa
urine specimen transport kit, as described by Groskopf et al.
[17]. Urine samples were processed and tested to quantify
messenger RNA (mRNA)-PCA3 and mRNA-PSA concen-
trations using the Progensa PCA3 assay (Gen-probe, San
Diego, CA). The PCA3 score was calculated as mRNA-
PCA3/mRNA-PSA  1,000.
Both p2PSA and, consequently, its derivates and PCA3
score for each patient were determined in the same
laboratory (NIC-Naples). RP specimens were evaluated
using 3-mm serially sectioned whole-mount specimens
according to the Stanford protocol [18] and primary and
secondary Gleason scores (GSs) were assigned by an
experienced uropathologist at each center, blinded to the
biomarkers value, according to the 2005 consensus confer-
ence of the International Society of Urological Pathology
deﬁnitions [19]. All tumor foci were identiﬁed, and
cumulative tumor volume (TV) was assessed using compu-
terized planimetry accounting for all of them [20].
2.3. Study end points
The primary end points of the study were to determine
the accuracy of PHI and PCA3 in predicting the presence
of TV 4 0.5 ml, extracapsular extension (ECE), semi-
nal vesicles invasions (SVI), pathologic GS sum Z7,
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considered the Epstein criteria [organ conﬁned disease,
TVr 0.5 ml, and no Gleason pattern 4/5] to exclude
pathologically conﬁrmed insigniﬁcant PCa) [21].
2.4. Statistical analysis
All statistical analyses were completed using SPSS v. 19
software (SPSS Inc, IBM Corp, Somers, NY). The qual-
itative data were tested using the Chi-square test or the
Fisher exact test as appropriate and the continuous variables
were tested using the Mann-Whitney U test or the Student
t test according to their distribution (according to
Kolmogorov-Smirnov test) and were presented as median
(interquartile range) or mean ( standard deviation), as
appropriate. Univariate and multivariate logistic regression
analyses were carried out to identify variables potentially
predictive of TV4 0.5 ml, pathologic GS sum Z7, ECE,
SVI, PCSPCa, from a model including age, body mass
index, total PSA (tPSA) level, fPSA level, PHI, PCA3 level,
prostate volume, biopsy GS, percentage of positive cores,
and clinical stage. Pathologic GS sum Z7 and PCSPCa
were evaluated in a subcohort of patients with GSr 6 on
biopsy.
We preferred to exclusively consider PHI and exclude
from the univariate and multivariate analysis both the
p2PSA and %p2PSA because the variable PHI could be
more easy to interpret and understand by the reader, as it is
generally evaluated in a clinical setting and because statisti-
cally speaking, PHI could capture much of the effects and
obscure results when evaluated in same multivariate anal-
ysis together with its components (p2PSA).
The predictive accuracy of the model was assessed in
terms of the area under the receiver operating characteristics
curve (AUC) value, incorporating all independent predic-
tors. For bootstrapping, 1,000 resamples were used for all
accuracy estimates and to reduce overﬁt bias. The Harrell
concordance index was used to assess discrimination and
was expressed as a value between 0.5 and 1.0, where 1.0
indicates perfect prediction.
The areas under the curve were compared via the
Mantel-Haenszel test. For all statistical comparisons, sig-
niﬁcance was considered as Po 0.05.3. Results
Table 1 summarizes the characteristics of patients
included in the analysis. Pathologic T2- and T3-category
disease was found in 102 (65.4%) and 54 patients (34.6%),
respectively. TV 4 0.5 ml was found in 128 patients
(82.1%), PCSPCa in 132 patients (84.6%), pathologic
Gleason sum Z7 in 104 patients (66.7%), ECE in 34
patients (21.8%), and SVI in 20 patients (12.8%). Table 2
lists the comparison of PSA derivatives according to study
end points. In detail, p2PSA, %p2PSA, PHI, and PCA3were signiﬁcantly increased in subjects with TV4 0.5 ml,
PCSPCa, pathologic GSZ 7, ECE, and SVI. On univariate
logistic regression analysis, PHI and PCA3 were accurate
predictors of the presence of TV 4 0.5 ml, PCSPCa, and
ECE, whereas only PHI predicted pathologic Gleason sum
Z7 and SVI (Supplementary Tables S1–S5).
Predictive accuracy was quantiﬁed as the AUC for each
outcome of interest and different cut-offs at different levels
of sensitivity and speciﬁcity were reported (Supplementary
Tables S6–S10).
On multivariate analyses and after bootstrapping with
1,000 resamples, the inclusion of PHI signiﬁcantly
increased the accuracy of a baseline multivariate model,
which included patient age, tPSA, fPSA, percentage of
positive cores, clinical stage (cT1c vs. cT2), prostate
volume, body mass index, and biopsy GS, in predicting
the study outcomes. Particularly, to predict TV4 0.5 ml,
the baseline model had an AUC of 89.3, which signiﬁcantly
increased by 7.9% with the addition of PHI (AUC ¼ 97.2,
P4 0.05), whereas PCA3 did not lead to a signiﬁcant
increase (AUC ¼ 92.1).
Although both PHI and PCA3 signiﬁcantly improved
predictive accuracy to predict ECE compared with the
baseline model achieving independent predictor status (all
P'so 0.01), only PHI led to a signiﬁcant improvement in
the prediction of SVI (AUC ¼ 92.2, Po 0.05 with a gain
of 3.6%).
In the subset with GSr 6, PHI signiﬁcantly improved
predictive accuracy by 7.6% compared with the baseline
model (AUC ¼ 89.7 vs. 97.3) to predict PCSPCa and by
5.9% compared with the baseline model (AUC ¼ 83.1 vs.
89.0) to predict pathologic GSZ 7. For these outcomes,
PCA3 did not add incremental predictive value (Tables 3–7).4. Discussion
In the current study, we investigated the accuracy of PHI
and PCA3 in predicting PCa characteristics at ﬁnal pathol-
ogy in a cohort of patients who underwent RP.
Although previous studies have separately determined
the accuracy of these markers in predicting the pathologic
features of PCa at the time of RP, to the best of our
knowledge, this is the ﬁrst study investigating these
relationships in the same cohort of patients.
On univariate analysis, we demonstrated that both PHI
and PCA3 were independent predictors of TV4 0.5 cm3,
PCSPCa, and ECE, whereas PHI but not PCA3 achieved
independent predictor status of more aggressive PCa
(pathologic Gleason sum Z7) and of SVI status. Multi-
variate analyses showed that the inclusion of PHI in
multivariate models signiﬁcantly increased the accuracy of
a baseline model in predicting the 5 pathologic outcomes.
The inclusion of PCA3 in multivariate models surprisingly
increased the accuracy of only ECE with statistical signiﬁ-
cance. Therefore, our current RP specimens–based results
Table 1
Patient characteristics and descriptive statistics
Patients characteristics (n ¼ 156) Mean
Age, mean (median)  SD (IQR) 64.0 (65.0)  5.2 (61.0–67.0)
BMI, mean (median)  SD (IQR) 27.2 (27.0)  4.4 (23.8–31.0)
tPSA, mean (median)  SD (IQR) 6.70 (6.1)  2.9 (4.5–8.3)
fPSA, mean (median)  SD (IQR) 1.00 (0.9)  0.5 (0.3–3.3)
%fPSA, mean (median)  SD (IQR) 0.30 (0.17)  1.5 (0.0–13.2)
p2PSA, mean (median)  SD (IQR) 26.8 (20.4)  19.4 (14.5–33.3)
%p2PSA, mean (median)  SD (IQR) 4.2 (2.3)  12.3 (1.8–2.9)
PHI, mean (median)  SD (IQR) 69.7 (54.2)  45.2 (40.0–84.3)
PCA3, mean (median)  SD (IQR) 79.5 (73.5)  50.6 (35.0–110.7)
PV, mean (median)  SD (IQR) 38.6 (49.0)  10.3 (30.0–69.0)
Percentage of positive cores, mean (median)  SD (IQR) 18.95 (16.0)  11.25 (11.0–27.0)
Digital rectal examination, n (%)
Negative 142 (91.0)
Positive 14 (9.0)
Clinical stage, n (%)
T1c 142 (91.0)
T2 14 (9.0)
Biopsy Gleason score, n (%)
r6 106 (67.9)
7 30 (19.2)
Z8 20 (12.8)
Tumor volume, ml, n (%)
r0.5 28 (17.9)
40.5 128 (82.1)
Insigniﬁcant PCa, n (%)
No 132 (84.6)
Yes 24 (15.4)
PRIAS criteria compatibility, n (%)
Yes 50 (32)
No 106 (68)
Epstein criteria compatibility, n (%)
Yes 62 (40)
No 94 (60)
Pathologic Gleason score, n (%)
r6 52 (33.3)
7 74 (47.4)
Z8 30 (19.2)
Pathologic category, n (%)
T2 102 (65.4)
T3a 34 (21.8)
T3b 20 (12.8)
Surgical margin, n (%)
R0 120 (77)
R1 36 (23)
Lymph nodal category, n (%)
N0 126 (81)
Nþ 30 (19)
BMI ¼ body mass index; IQR ¼ interquartile range; PRIAS ¼ Prostate Cancer Research International: Active Surveillance; PV ¼ prostate volume.
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PCA3 the presence of both TV4 0.5 cm3 and PCSPCa
and also of more aggressive and extended PCa (pathologic
Gleason sum Z7, ECE and SVI), and it could be used to
stratify the risk of clinically insigniﬁcant or signiﬁcant PCaat ﬁnal pathology and be adopted in preoperative counsel-
ing to set clinical decision-making processes.
Several studies have aimed to clarify, in separate study
cohorts, the potential role of these new biomarkers in
predicting pathologic features of PCa at ﬁnal pathology.
Table 2
Head-to-head comparison of variables according to tumor volume 40.5 cm3, signiﬁcant PCa, pathologic Gleason score Z7, pathologic categoryZT3, and seminal vesicle invasion
Tumor volume Signiﬁcant PCa Pathologic Gleason score Pathologic categoryZT3 Seminal vesicle invasion
r0.5 40.5 Yes No o7 Z7 No Yes No Yes
Age (y), median (IQR)* 65.0 (62.0–
67.75)
65.0 (61.0–66.0) 65.0 (62.0–67.0) 65.0 (61.0–
67.5)
64.0 (21.0–
68.0)
65.0 (61.25–
67.0)
65.0 (61.0–68.0) 66.0 (63.5–69.0) 65.0 (61.0–
67.0)
64.0 (61.0–68.0)
P value 0.97 0.98 0.59 0.70 0.61
BMI (kg/m2), median (IQR)* 28.2 (23.0–32.0) 26.1 (23.9–29.0) 26.5 (24.0–29.4) 27.0 (22.5–
31.9)
26.2 (24.0–
31.0)
27.0 (24.0–31.0) 27.0 (24.0–31.0) 24.9 (24.0–28.2) 27.0 (23.9–
31.0)
26.9 (23.2–31.6)
P value 0.59 0.99 0.33 0.52 0.91
tPSA (ng/ml), median
(IQR)*
4.1 (3.2–4.8) 6.9 (5.0–8.6) 6.9 (4.9–8.5) 4.1 (3.2–4.8) 4.6 (3.9–6.3) 7.2 (5.1–8.9) 6.1 (4.5–7.9) 8.2 (5.1–9.4) 5.6 (4.9–8.2) 7.4 (6.1–9.0)
P value o0.01 o0.01 o0.01 o0.01 0.31
fPSA (ng/ml), median
(IQR)*
0.82 (0.66–0.94) 0.91 (0.69–1.30) 0.91 (0.69–1.30) 0.82 (0.65–
0.93)
0.90 (0.69–
1.23)
0.85 (0.77–1.16) 0.86 (0.69–1.16) 1.15 (0.77–1.30) 0.87 (0.66–
1.28)
0.89 (0.71–1.16)
P value 0.19 0.18 0.90 0.49 0.75
% Free PSA, median (IQR)* 0.19 (0.16–0.26) 0.12 (0.11–0.20) 0.16 (0.11–0.20) 0.19 (0.14–
0.26)
0.19 (0.16–
0.26)
0.15 (0.10–0.19) 0.317 (0.12–
0.22)
0.14 (0.10–0.18) 0.17 (0.12–
0.22)
0.12 (0.10–0.16)
P value 0.66 0.69 o0.01 0.59 o0.05
p2PSA (pg/ml), median
(IQR)*
12.7 (8.8–15.7) 23.2 (16.3–35.5) 23.2 (16.1–34.7) 12.7 (7.8–15.5) 16.2 (12.3–
22.8)
23.4 (15.8–35.5) 19.9 (13.9–25.8) 30.6 (19.7–43.8) 19.8 (14.1–
30.2)
36.5 (23.2–51.2)
P value o0.01 o0.01 0.02 0.03 o0.01
%p2PSA, median (IQR)* 1.7 (1.1–1.9) 2.5 (1.9–3.3) 2.5 (1.8–3.2) 1.7 (1.1–1.9) 1.8 (1.5–2.2) 2.6 (2.0–3.5) 2.1 (1.7–2.8) 2.9 (2.1–3.6) 2.1 (1.8–2.9) 4.3 (2.8–7.4)
P value o0.01 o0.01 o0.01 o0.01 o0.01
PHI, median (IQR)* 34.4 (23.7–38.2) 62.3 (47.3–93.9) 61.3 (46.2–93.8) 34.4 (25.4–
37.6)
38.2 (32.6–
49.9)
65.4 (50.8–98.9) 49.9 (38.2–71.6) 81.7 (56.6–
106.9)
52.1 (39.2–
77.9)
107.1 (69.1–
147.4)
P value o0.01 o0.01 o0.01 o0.01 o0.01
PCA3, median (IQR)* 29.0 (22.0–35.0) 81.0 (53.5–
123.0)
61.3 (52.0–
123.0)
25.0 (22.0–
34.0)
33.0 (24.0–
78.0)
85.5 (58.5–
124.0)
66.0 (33.0–93.0) 98.0 (81.0–
123.0)
70.0 (33.0–
98.0)
125.0 (80.0–
134.0)
P value o0.01 o0.01 o0.01 o0.01 0.02
Prostate volume (cc),
median (IQR)*
39.45 (33.5–
45.0)
33.0 (25.0–43.0) 39.0 (33.0–45.0) 36.6 (28.5–
43.0)
39.5 (30.0–
50.0)
39.0 (33.0–45.0) 39.0 (30.0–45.0) 39.9 (34.5–40.0) 39.9 (30.0–45.) 35.0 (33.0–45.)
P value 0.111 0.48 0.65 0.90 0.36
Percentage of positive
cores, median (IQR)*
22.0 (11.0–27.0) 8.0 (5.0–11.0) 19.0 (11.0–27.0) 8.0 (5.0–11.) 11.0 (5.0–16.0) 27.0 (11.0–27.0) 16.0 (11.0–27.0) 22.0 (11.0–27.0) 16.0 (11.0–
27.0)
27.0 (27.0–38.0)
P value o0.01 o0.01 o0.01 o0.01 o0.01
BMI ¼ body mass index; IQR ¼ interquartile range.
*Mann-Whitney test.
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Table 3
Multivariate analysis predicting the probability of tumor volume 40.5 ml
Predictors Baseline modela OR
(95% CI)
P value Baseline model
with PHIa OR (95% CI)
P value Baseline model with PCA3a
OR (95% CI)
P value
Age 1.00 (0.91–1.10) 0.77 1.33 (1.01–1.75) 0.04 0.96 (0.84–1.09) 0.72
fPSA 0.21 (0.00–39.35) 0.5 0.34 (0.12–0.67) 0.47 0.38 (0.00–57.52) 0.71
tPSA 4.51 (1.16–17.61) 0.03 7.36 (2.17–25.10) o0.01 3.03 (1.69–53.48) o0.01
%PC 1.25 (1.10–1.42) o0.01 1.40 (1.14–1.71) o0.01 1.22 (1.05–1.41) o0.01
PHI – – 1.36 (1.11–1.67) o0.01 – –
PCA3 – – – 1.04 (1.00–1.07) 0.02
AUC of multivariate
models, %
89.3 – 97.2b 92.1
Gain in predictive
accuracy, %
7.9b 2.8
%PC ¼ percentage of positive cores; AUC ¼ area under the curve; OR ¼ odds ratio.
aAdjusted for clinical stage (T1c vs. T2), prostate volume, body mass index (BMI), and biopsy Gleason score (r6 vs. Z7).
bPo 0.05 vs. baseline model on Mantel-Haenszel test.
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esis that PCA3 score was a signiﬁcant predictor of low-
volume disease [5–9] and PCSPCa [7–9]. Hessels et al. [10]
did not conﬁrm these correlations, but the number of RP
specimens included in their study was small and the patient
cohort was also different, including few men with favorable
features. In addition, van Gils et al. [11] in their study did
not prove the prognostic value of PCA3 but the study
cohort was based on only 62 RP specimens, emphasizing
the need of further research with larger number of patients.
As in our study, Whitman et al. found a statistically
signiﬁcant association between PCA3 and ECE; whereas,
regarding the association between PCA3 and aggressive
disease, deﬁned as GS sum Z7, several studies demon-
strated limited predictive capability, showing that PCA3 did
not emerge, at multivariate logistic regression analysis, as
an independent risk factor of more aggressive PCa [7–9].
Similarly, some studies have analyzed the predictive role
of p2PSA, %p2PSA, and PHI on RP ﬁndings, conﬁrming
the predictive capability for aggressive cancer already seen
during the time of biopsy [12,13,15]. For instance, Guaz-
zoni et al. [14] have found that %p2PSA and PHI were
accurate predictors of several PCa characteristics at ﬁnalTable 4
Multivariate analysis predicting the probability of pathologically conﬁrmed signi
Predictors Baseline modelb
OR (95% CI)
P value Baseline m
OR (95%
Age 0.99 (0.87–1.13) 0.94 1.15 (0.93
fPSA 0.86 (0.11–6.56) 0.88 0.56 (0.05
tPSA 2.71 (1.54–4.74) o0.01 4.49 (1.84
%PC 1.22 (1.08–1.38) o0.01 1.25 (1.09
PHI – – 1.22 (1.09
PCA3 – – –
AUC of multivariate models, % 89.7 – 97.3
Gain in predictive accuracy, % – – 7.6c
%PC ¼ percentage of positive cores; AUC ¼ area under the curve; OR ¼
aCohort included 106 patients (67.9%) with biopsy Gleason scorer6.
bAdjusted for clinical stage (T1c vs. T2), prostate volume, and body mass ind
cPo 0.05 vs. baseline model on Mantel-Haenszel test.pathology, showing as, in a multivariate analysis, that their
inclusion in a baseline model (including age, tPSA, fPSA,
free/total PSA, clinical stage, and biopsy GS) signiﬁcantly
increased the accuracy in the prediction of high pathologic
category and grade.
The capability to discriminate between insigniﬁcant or
signiﬁcant PCa at ﬁnal pathology of these new biomarkers
should be considered relevant because approximately one-
third of new diagnosed tumors have features of insigniﬁcant
PCa [22], and these patients may be candidates for AS. AS
aims to delay or avoid radical treatment (RP or radiation
therapy) and its related morbidity without compromising
survival [23]. However, even with the most rigid selection
criteria, several patients with apparently low-risk PCa might
harbor unfavorable disease owing to inaccuracies in cur-
rently used tools, also in biopsy protocols that, in addition,
are invasive and might alter the quality of care for these
patients. Conversely, the current AS criteria might also be
too strict, thereby excluding some patients in whom expect-
ant management would be appropriate and safe. For these
reasons, several studies have also analyzed the role of
p2PSA, its derivates, and PCA3 in predicting RP ﬁndings in
this clinical setting. Tosoian et al. [24] found that baselineﬁcant PCaa
odel with PHIb
CI)
P value Baseline model with PCA3b
OR (95% CI)
P value
–1.41) 0.18 0.91 (0.78–1.06) 0.23
–6.94) 0.65 0.27 (0.07–27.28) 0.39
–10.93) o0.01 2.79 (1.26–6.21) o0.01
–1.43) o0.01 1.16 (0.99–1.37) 0.06
–1.37) o0.01 – –
– 1.09 (1.02–1.16) o0.01
93.0
3.3
odds ratio.
ex (BMI).
Table 5
Multivariate analysis predicting the probability of pathologic Gleason scoreZ7a
Predictors Baseline modelb
OR (95% CI)
P value Baseline model with
PHIb OR (95% CI)
P value Baseline model with PCA3b
OR (95% CI)
P value
Age 0.89 (0.80–0.99) 0.04 0.90 (0.80–1.01) 0.08 0.89 (0.80–0.99) 0.04
fPSA 0.80 (0.36–3.92) 0.76 1.24 (0.38–4.02) 0.72 0.74 (0.26–2.08) 0.57
tPSA 1.66 (1.25–2.20) o0.01 1.56 (1.14–2.15) o0.01 1.66 (1.25–2.20) o0.01
%PC 1.13 (1.06–1.20) o0.01 1.13 (1.06–1.20) o0.01 1.13 (1.06–1.20) o0.01
PHI – – 1.02 (0.990–1.02) o0.01 – –
PCA3 – – – – 1.01 (0.99–1.01) 0.64
AUC of multivariate models, % 83.1 – 89.0 – 84.5 –
Gain in predictive accuracy, % – 5.9c – 1.4 –
%PC ¼ percentage of positive cores; AUC ¼ area under the curve; OR ¼ odds ratio.
aCohort included 106 patients (67.9%) with biopsy Gleason scorer6.
bAdjusted for clinical stage (T1c vs. T2), prostate volume, and body mass index (BMI).
cPo 0.05 vs. baseline model on Mantel-Haenszel test.
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p2PSA to free/total PSA ratio (%fPSA), and PHI were
predictive of reclassiﬁcation at repeat biopsy during a long-
term follow-up (median ¼ 4.3 y) in low-risk patients who
underwent to AS. These results were comparable to those
recently obtained in an Asians cohort by Hirama et al. [25]
showing that %p2PSA and PHI were independent predic-
tive factors for pathologic upgrade at 1 year after AS
commencement. Finally, another study showed that the
ratio of p2PSA to %fPSA in the serum at diagnosis was
higher in men developing unfavorable ﬁndings on repeat
biopsy and recently the same study group also showed that,
in multivariate analysis, PHI and p2PSA to %fPSA,
combined with biopsy tissue DNA content in benign and
cancer areas, improved its accuracy in the prediction of
unfavorable conversion biopsy ﬁndings at the annual
surveillance biopsy examination [26].
With regard to PCA3, Tosoian et al. [27] also studied
PCA3 within the Johns Hopkins surveillance program
showing that, in patients with low-risk PCa who were
carefully selected for AS, the PCA3 score was not
signiﬁcantly associated with short-term biopsy upgrading,
failing to predict biological and clinical progression. In
contrast, Ploussard et al. [9] and Nakanishi et al. [5]Table 6
Multivariate analysis predicting the probability of ECE
Predictors Baseline modela
OR (95% CI)
P value Ba
PH
Age 1.03 (0.949–1.123) 0.46 1.0
fPSA 0.80 (0.302–2.145) 0.66 0.7
tPSA 1.21 (1.047–1.407) o0.01 1.2
%PC 0.98 (0.94–1.02) 0.34 0.9
PHI – – 1.0
PCA3 – –
AUC of multivariate models, % 70.4 – 78
Gain in predictive accuracy, % – – 8.0
%PC ¼ percentage of positive cores; AUC ¼ area under the curve; OR ¼
aAdjusted for clinical stage (T1c vs. T2), prostate volume, body mass index (
bPo 0.05 vs. baseline model at Mantel-Haenszel test.supported the hypothesis that PCA3 score may apply in
selecting men who have low-volume/low-grade PCa and are
eligible for AS, showing a direct correlation between PCA3
scores with GS and PCa volume at ﬁnal pathology.
Our study has some strength. It is a prospective
observational cohort study in which, for the ﬁrst time, the
prognostic performances of PCA3 and PHI are contextually
evaluated on the histological ﬁndings on RP. In addition, all
blood samples and urine samples were evaluated in the
same laboratory to overcome the potential interlaboratory
variability. Despite its strengths, our study is not devoid of
limitations. This study is limited by its relatively small
sample size of a single cohort of white patients and
therefore its clinical ﬁndings should be further externally
conﬁrmed. We did not adopt a standardized and centralized
pathologic evaluation and, consequently, pathologic exami-
nations were performed by different pathologists. In this
context, we did not have a second reference pathologist to
conﬁrm our ﬁndings. In addition, we did not evaluate the
inclusion of PHI or PCA3 in predictive nomograms, which
are often used for PCa prognosis, and we did not compare
PHI and PCA3 with PSA density and PSA velocity.
However, several studies have shown that PSA density
and PSA velocity did not enhance the predictive accuracyseline model with
Ia OR (95% CI)
P value Baseline model with
PCA3a OR (95% CI)
P value
4 (0.96–1.14) 0.34 1.01 (0.92–1.11) 0.82
8 (0.28–2.21) 0.64 1.00 (0.32–3.08) 0.99
6 (1.10–1.46) o0.01 1.08 (0.90–1.30) 0.41
7 (0.92–1.02) 0.19 0.96 (0.92–1.01) 0.10
1 (1.00–1.02) o0.01 – –
1.07 (1.01–1.03) o0.01
.4 77.4
b 7.0b
odds ratio.
BMI), and biopsy Gleason score (r6 vs. Z7).
Table 7
Multivariate analysis predicting the probability of seminal vesicle invasion
Predictors Baseline modela
OR (95% CI)
P value Baseline model with PHIa
OR (95% CI)
P value Baseline model with PCA3a
OR (95% CI)
P value
Age 0.90 (0.80–1.02) 0.07 0.91 (0.81–1.03) 0.13 0.88 (0.78–1.00) 0.06
fPSA 3.17 (0.78–12.93) 0.19 2.86 (0.63–12.89) 0.17 4.34 (0.86–21.91) 0.07
tPSA 0.96 (0.76–1.21) 0.74 0.96 (0.77–1.20) 0.71 0.89 (0.69–1.15) 0.37
%PC 1.16 (1.09–1.24) o0.01 1.15 (1.08–1.22) o0.01 1.16 (1.09–1.24) o0.01
PHI – – 1.01 (1.00–1.02) 0.02 – –
PCA3 – – 1.01 (1.00–1.038) 0.15
AUC of multivariate models, % 88.6 – 92.2 89.6 –
Gain in predictive
accuracy, %
– – 3.6b 1.0 –
%PC ¼ percentage of positive cores; AUC ¼ area under the curve; OR ¼ odds ratio.
aAdjusted for clinical stage (T1c vs. T2), prostate volume, body mass index (BMI), and biopsy Gleason score (r6 vs. Z7).
bPo 0.05 vs. baseline model on Mantel-Haenszel test.
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[28,29].
In summary, we strongly believe that a one-size-ﬁts-all
approach to the PCa treatment is far from optimal and should
be abandoned in favor of an individualized risk-stratiﬁed
approach to choose the best treatment option for every
patient. In this context, the use of a blood test to evaluate
PHI may be cheaper and more practical than other more
sophisticated tests (i.e., genomic tests), and it does not
require vigorous rectal examination (i.e., PCA3). Certainly,
the overall cost of these new biomarkers could limit their
widespread use. However, PHI is less expensive than other
available tests, and this should be considered when making a
choice of the best biomarker, together with its clinical
validity [30]. Furthermore, being able to estimate the risk
of adverse pathologic characteristics could help in selecting
preoperative candidates for new imaging methods such as
multiparametric magnetic resonance imaging staging. We
believe that the association with magnetic resonance imaging
could represent a promising combination that would change
preoperative therapeutic decision in selective patients with
PCa. Unfortunately, no studies are actually available on this
potential association with prognostic purposes. Therefore, we
are aware that this will require ongoing commitment from
researchers and physicians and further studies are still needed
to develop the optimal tools in this setting of patients.5. Conclusion
In this study, we showed that, in a cohort of patients
underwent RP, PHI is signiﬁcantly better than PCA3 in
discriminating both the presence of more aggressive (patho-
logic Gleason sumZ7,) and extended PCa (ECE and SVI),
but further and larger studies are required to externally
validate our ﬁndings. In our clinical practice, we should
begin to consider these new biomarkers as part of the
urologic armamentarium during the risk stratiﬁcation and
treatment selection in patients with PCa.Appendix A. Supporting Information
Supplementary material cited in this article is available
online at http://dx.doi.org/10.1016/j.urolonc.2014.12.002.References
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